Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Psoriasis and Depression: A Comprehensive Review for Clinicians

Psoriasis and Depression: A Comprehensive Review for Clinicians Psoriasis has various systemic comorbidities including psychiatric disorders. Due to limited experience of dermatologists, psychiatric comorbidities are often not adequately addressed or treated. Recently, the association between depression, a risk factor for suicidality, and psoriasis has become a topic of interest due to suicides occurring in patients on new therapies such as apremilast and brodalumab for the treatment of psoriasis. A systematic literature search was conducted to provide an overview for clinicians on the epidemiological relationship between depression and psoriasis. Although there seems to be higher prevalence of depression in patients with psoriasis compared to non-psoriatic patients, the estimated prevalence of the comorbidity varies greatly and does not necessarily correlate with severity of psoriasis. Given the clear increased risk and association of depression with psoriasis, it is plausible that depression is not directly linked with the apremilast or brodalumab, but rather with psoriasis itself. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

Psoriasis and Depression: A Comprehensive Review for Clinicians

Loading next page...
 
/lp/sage/psoriasis-and-depression-a-comprehensive-review-for-clinicians-L580pCIGU3

References (79)

Publisher
SAGE
Copyright
© 2017 National Psoriasis Foundation.
ISSN
2475-5303
eISSN
2475-5311
DOI
10.1177/247553031700200304
Publisher site
See Article on Publisher Site

Abstract

Psoriasis has various systemic comorbidities including psychiatric disorders. Due to limited experience of dermatologists, psychiatric comorbidities are often not adequately addressed or treated. Recently, the association between depression, a risk factor for suicidality, and psoriasis has become a topic of interest due to suicides occurring in patients on new therapies such as apremilast and brodalumab for the treatment of psoriasis. A systematic literature search was conducted to provide an overview for clinicians on the epidemiological relationship between depression and psoriasis. Although there seems to be higher prevalence of depression in patients with psoriasis compared to non-psoriatic patients, the estimated prevalence of the comorbidity varies greatly and does not necessarily correlate with severity of psoriasis. Given the clear increased risk and association of depression with psoriasis, it is plausible that depression is not directly linked with the apremilast or brodalumab, but rather with psoriasis itself.

Journal

Journal of Psoriasis and Psoriatic ArthritisSAGE

Published: Jun 1, 2017

There are no references for this article.